Menu
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Buy Currently
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Sample Portfolio
Sample Portfolio Analysis
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Account Requirements
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
Municipal Bond Presentation
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
home
about us
Investment Approach
Client Service Approach
Market Analysis Summary
Mission Statement
Value Proposition
Team Biographies
Firm ADV PDFs
Form CRS
Firm Brochure-Part 2A of Form ADV
Brochure Supplement Amit Stavinsky
Brochure Supplement Frank Parks
Brochure Supplement Dominick Savo
Brochure Supplement Richard Mason
Brochure Supplement Joe Estes
Brochure Supplement Jonathan Ezra
Statement Of Financial Strength
Job Opportunities
Tamar Advisors
Own Your Practice
Letter to Clients
member log-in
contact us
PRODUCTS
Fixed Income Portfolio (FIP)
FIP Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Market (TAM)
TAM sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Fund (TAF)
TAF sm Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Market Value Securities (MVS)
MVS Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Total Asset Value (TAV)
TAV Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
Municipal Bonds
Taxable Bonds
Par, Premium, and Discount Bonds
Rating and Analyzing Bonds
Refunding & Pre-refunding
Bond Yields
Yield Curve
Secured Bonds
Mortgage Bonds
Unsecured Bonds
Debentures
Subordinated Debentures
Zero-Coupon Bonds
Convertible Bonds
High Yield Dividend Stocks
Independent Money Managers
Fees & Compensation
Corporate Cash Management
Fees & Compensation
Estate Planning
Financial Planning
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
Professional Alliance Network
Client Service Approach
Client's Responsibilities
Fees
Implementation
Legal Services
Termination
MUNICIPAL BONDS
Municipal Bond Presentation
About Us
The Management
Global Asset Allocation Products
FIP Program
Classifying Municipal Bonds
Revenue Bonds
Credit Factors Affecting General Obligation Bonds
Credit Factors Affecting the Quality of Local Municipal Bonds
Analyzing the Credit Quality of General Obligation Bonds
Analyzing the Credit Quality of Revenue Municipal Bonds
What We Normally Buy
What We Normally Don’t Buy
Municipal Bonds – Unique Asset Class
Default Rates
Yield Difference
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same-Day Allocation
TSL’s Turnkey Operation Platform
Classifying Municipal Bonds
Revenue Municipal Bonds
Types of Revenue Municipal Bonds
Industrial Development Revenue Bonds
Lease-back Bonds
Special Tax Bonds
NHA/PHA Bonds
Moral Obligation Bonds
Municipal Notes
TANs/RANs
BANs
CLNs/GANs
Variable Rate Bonds/Notes
Build America Bonds
Double-Barreled Bonds
Bond Index Components
Open-end-Closed-end-Indenture
Sinking Fund
Bond Contracts
Bond Indenture
Official Statement
Bond Issuance Process
Analyzing GO Bonds
Analyzing Revenue Bonds
Debt Ratios
General Price Analysis of Municipal Bonds
Liquidity
Interest Rate Risk
Credit Risk
Coupon Risk
Maturity Risk
Municipal Bond Insurance
Municipal Bonds Unique Asset Class
Default Rates
What We Buy Currently
What We Normally Don’t Buy
Turnkey Operation Platform
Advantages of Our Bid Wanted System
Advantages of Our Clearing System
Preferred Custodian Settlement
Advantages of Same Day Allocation
Traditional Broker/Dealer Execution Flow
TSL's Turnkey Operation Platform
INDEX FUNDS
Total Asset Fund (TAF)
TAF® Program
Services, Fees and Compensation
Client Information
Client Contact with Portfolio Manager(s)
Additional Information
Sample Portfolio
Back Dated Performance Reports
Quarterly Performance Reports
EVENTS
FIP
Event Schedule
TAM
Event Schedule
Total Asset Market (TAM sm) Presentation
TAF
Event Schedule
Total Asset Fund (TAF sm) Presentation
MVS
Event Schedule
Market Value Securities (MVS sm) Presentation
Featured Event
Calendar of Events
Events History
Investing During Uncertain Times
Read FULL Seminar Here
Tax-Free Income Seminar
Bond Fund Seminar
RSVP-Signup Form
MARKET RESEARCH
Featured Quarterly Newsletter
Featured Articles
Contrarian Notes Blog
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
10x Genomics, Inc. - Common Stock
(NQ:
TXG
)
24.55
+0.87 (+3.65%)
Streaming Delayed Price
Updated: 11:50 AM EDT, May 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about 10x Genomics, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
1 Small-Cap Stock for Long-Term Investors and 2 We Avoid
November 11, 2025
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small...
Via
StockStory
Why 10x Genomics (TXG) Stock Is Trading Up Today
November 11, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 0.6% in the afternoon session after Canaccord Genuity Group raised its price target on the stock. The analyst firm lifted its target to $19.00...
Via
StockStory
Topics
Artificial Intelligence
Supply Chain
Spotting Winners: PacBio (NASDAQ:PACB) And Life Sciences Tools & Services Stocks In Q3
November 10, 2025
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at PacBio (NASDAQ:PACB) and the best and worst...
Via
StockStory
Topics
Artificial Intelligence
Earnings Scheduled For November 6, 2025
↗
November 06, 2025
Via
Benzinga
Earnings Scheduled For November 5, 2025
↗
November 05, 2025
Via
Benzinga
Analyst Expectations For 10x Genomics's Future
↗
October 23, 2025
Via
Benzinga
3 Russell 2000 Stocks We Approach with Caution
November 09, 2025
The Russell 2000 (^RUT) is packed with potential breakout stocks, thanks to its focus on smaller companies with high growth potential. However, smaller size also means these businesses often lack the...
Via
StockStory
Topics
Retirement
Why 10x Genomics (TXG) Stock Is Trading Up Today
November 07, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 14.3% in the afternoon session after the company reported third-quarter financial results that beat Wall Street's expectations and provided an...
Via
StockStory
Topics
Artificial Intelligence
TXG Q3 Deep Dive: Spatial Biology and Consumables Drive Outperformance Amid Macro Uncertainty
November 07, 2025
Biotech company 10x Genomics (NASDAQ:TXG) beat Wall Street’s revenue expectations in Q3 CY2025, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s revenue guidance...
Via
StockStory
12 Health Care Stocks Moving In Friday's Pre-Market Session
↗
November 07, 2025
Via
Benzinga
10X Genomics (NASDAQ:TXG) Surges 13% on Q3 Revenue Beat and Strong Guidance
↗
November 06, 2025
10x Genomics (TXG) stock surged over 13% after beating Q3 2025 earnings estimates and providing strong Q4 revenue guidance, signaling investor optimism.
Via
Chartmill
10x Genomics’s (NASDAQ:TXG) Q3: Strong Sales, Stock Jumps 13.1%
November 06, 2025
Biotech company 10x Genomics (NASDAQ:TXG) reported Q3 CY2025 results beating Wall Street’s revenue expectations, but sales fell by 1.7% year on year to $149 million. On top of that, next quarter’s...
Via
StockStory
Mark Zuckerberg’s Chan Zuckerberg Initiative Bets Big on AI to Conquer All Diseases
November 06, 2025
The Chan Zuckerberg Initiative (CZI), founded by Priscilla Chan and Mark Zuckerberg, is placing artificial intelligence at the very heart of its audacious mission: to cure, prevent, or manage all...
Via
TokenRing AI
Topics
Artificial Intelligence
10x Genomics Earnings: What To Look For From TXG
November 04, 2025
Biotech company 10x Genomics (NASDAQ:TXG) will be reporting results this Thursday after market hours. Here’s what investors should know.
Via
StockStory
Lancaster Opens $7 Million Position in 10x Genomics (TXG)
↗
October 24, 2025
Lancaster Opens $7 Million Position in 10x Genomics (TXG)
Via
The Motley Fool
3 Healthcare Stocks Walking a Fine Line
October 24, 2025
Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. But financial performance has lagged recently as players offloaded surplus COVID...
Via
StockStory
Topics
Stocks
10x Genomics Partners With Anthropic To Bring AI Tools For Researchers
↗
October 20, 2025
10x Genomics is partnering with Anthropic to integrate its single cell and spatial biology analysis tools into Claude for Life Sciences.
Via
Stocktwits
Topics
Artificial Intelligence
Why Is 10x Genomics (TXG) Stock Rocketing Higher Today
October 20, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 6% in the morning session after BofA Securities maintained its "Buy" rating on the stock, even while lowering its price target.
Via
StockStory
Topics
Artificial Intelligence
Why 10x Genomics (TXG) Stock Is Trading Up Today
October 15, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 1.5% in the afternoon session after it announced a strategic partnership with SPT Labtech, a laboratory automation company, to provide...
Via
StockStory
Topics
Economy
Government
World Trade
Cathie Wood Warns Wall Street Is Missing AI's Biggest Opportunity In Healthcare, Calling It 'Sleeper' Investment Poised For Massive Returns
↗
October 15, 2025
Cathie Wood, CEO of Ark Invest, believes healthcare is the most profound application of AI and Wall Street is overlooking its potential.
Via
Benzinga
Topics
Artificial Intelligence
3 Unprofitable Stocks with Questionable Fundamentals
October 13, 2025
Running at a loss can be a red flag. Many of these businesses face mounting challenges as competition increases and funding becomes harder to secure.
Via
StockStory
Topics
Artificial Intelligence
10x Genomics, BioMarin Pharmaceutical, AMN Healthcare Services, Illumina, and Moderna Stocks Trade Down, What You Need To Know
October 10, 2025
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Via
StockStory
Topics
Economy
Government
World Trade
My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years
↗
September 18, 2025
Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
Via
Benzinga
3 Stocks Under $50 We Find Risky
September 16, 2025
Stocks trading between $10 and $50 can be particularly interesting as they frequently represent businesses that have survived their early challenges. However, investors should remain vigilant as some...
Via
StockStory
10x Genomics (TXG) Stock Trades Down, Here Is Why
September 12, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) fell 2.4% in the afternoon session after the stock extended its negative momentum as Piper Sandler initiated coverage of the stock with a Neutral...
Via
StockStory
Topics
Artificial Intelligence
10x Genomics (TXG) Stock Is Up, What You Need To Know
September 11, 2025
Shares of biotech company 10x Genomics (NASDAQ:TXG) jumped 2.1% in the morning session after Piper Sandler initiated coverage on the stock with a Neutral rating and a $15.00 price target.
Via
StockStory
Topics
Economy
Expert Outlook: 10x Genomics Through The Eyes Of 6 Analysts
↗
September 11, 2025
Via
Benzinga
This Eaton Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday
↗
September 11, 2025
Via
Benzinga
2 Cash-Heavy Stocks to Own for Decades and 1 We Turn Down
September 11, 2025
Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...
Via
StockStory
Boston Scientific, U.S. Physical Therapy, 10x Genomics, GE HealthCare, and Integer Holdings Shares Are Falling, What You Need To Know
September 10, 2025
A number of stocks fell in the afternoon session after markets pulled back, reversing early gains, as investor sentiment remained cautious despite a softer-than-expected inflation reading.
Via
StockStory
Topics
Economy
Government
Law Enforcement
< Previous
1
2
3
4
5
6
7
8
9
...
12
13
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.